Phäochromozytom und Paragangliom

  • E. Schuppert
  • H.-J. Schmoll

Zusammenfassung

Häufigkeit: Ein Phäochromozytom ist in 0,1% der Fälle Ursache eines Hypertonus. Autopsieergebnisse legen aber nahe, daß die wirkliche Prävalenz wahrscheinlich höher ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Averbuch ASD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 109: 267–273PubMedCrossRefGoogle Scholar
  2. Bravo EL (1991) Diagnosis of pheochromocytoma: Reflections on a controversy. Hypertension 17: 742–744PubMedCrossRefGoogle Scholar
  3. Brodgen RN, Heel RC, Speight TM,. Avery GS (1981) Alpha-methyl-parathyrosine: A review of its pharmacology and clinical use. Drugs 21:81–89CrossRefGoogle Scholar
  4. Hauptmann JB, Modlinger RS, Ertel NH (1983) Pheochromocytoma resistent to alpha-adrenergic blockade. Arch Intern Med 143:2321–2323CrossRefGoogle Scholar
  5. Hofstra RMW, Landsvater RM, Ceccherini I et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia typ 2B and sporadic medullary thyroid carcinoma. Nature 367: 375–376PubMedCrossRefGoogle Scholar
  6. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED (1987) Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med 13: 793–797CrossRefGoogle Scholar
  7. Krempf M, Lumbroso J, Mornex R et al. (1991) Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72: 455–461PubMedCrossRefGoogle Scholar
  8. Landsberg L, Young JB (1992) Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW (eds) Williams textbook of endocrinology, 8nd edn. Saunders, Philadelphia, pp 621–705Google Scholar
  9. Lehnert H, Dörr H.-G, Ziegler R (1993) Nebennierenmark. In: Ziegler R, Pickardt CR, Willig R.-P. (eds) Rationelle Diagnostik in der Endokrinologie einschließlich Diabetologie and Stoffwechsel. Thieme, Stuttgart New York, S 167–185Google Scholar
  10. Lips CJ, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ et al. (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A [see comments]. N Engl J Med 331: 828–835PubMedCrossRefGoogle Scholar
  11. Löhrs U (1987) Morphologische und immunhistochemische Befunde bei malignen endokrinen Tumoren. In: Engelhardt D, Mann K (eds) Endokrin-aktive maligne Tumoren. Springer, Berlin Heidelberg New York Tokyo, S 1–10CrossRefGoogle Scholar
  12. Mathew CGP, Smith BA, Thorpe K, Wong Z, Royle NJ, Jeffreys AJ, Ponder BAJ (1987) Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 328: 525–526Google Scholar
  13. Mattrey RF, DeRoo TR (1992) Magnetic resonance Imaging of the endocrine glands: Thyroid, parathyroid, and adrenal. In: Wilson JD, Bagdade JD (editorin-chief) Year book of endocrinology. Mosby Year Book, St. Louis/MO, pp XXI-XXXIVGoogle Scholar
  14. Reubi JC, Waser B, Khosla S et al. (1992) In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74: 1082–1089PubMedCrossRefGoogle Scholar
  15. Sailer B, Jacob K, Markl A, Zwiebel FM, Engelhardt D, Mann K (1989) Rezidivierende Hochdruckkrisen und Dyspnoe nach einseitiger Adrenalektomie wegen Phäochromozytom bei einer 44jährigen Patientin. Internist 31: 78–81Google Scholar
  16. Schuppert F, Scheumann G, Schöber C et al. (1991) Therapie eines malignen sympathischen Paraganglioms des Zuckerkandlschen Organs–ein Fallbericht. Klin Wochenschr 69: 937–942PubMedCrossRefGoogle Scholar
  17. Schürmeyer TH, Dralle H, Schuppert F, von zur Mühlen A (1988) Präoperative Diagnostik bei Verdacht auf Phäochromozytom-retrospektive Beurteilung diagnostischer Kriterien. Acta Med Austriaca 4: 106Google Scholar
  18. Serri O, Comtois R, Bettez P, Dubuc P, Buu NT, Kuchel O (1984) Reduction in the size of a pheochromocytoma pulmonary metastasis by metyrosine therapy. N Engl J Med 310: 1264–1265PubMedCrossRefGoogle Scholar
  19. Sheps SG, Jiang NS, Klee GG, Van Heerden JA (1990) Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc 65: 88–95PubMedCrossRefGoogle Scholar
  20. Sisson J, Frager MS, Valk TW et al. (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305: 12–17PubMedCrossRefGoogle Scholar
  21. Takeda M, Katagiri A, Kanai T et al. (1991) Treatment of malignant pehochromocytoma by combination of CVD regimen and transarterial embolization. Nippon Hinyokika Gakkai Zasshi 82: 826–829PubMedGoogle Scholar
  22. Tippett PA, McEwan AJ, Ackery DM (1986) A re-evaluation of dopamine excretion in pheochromocytoma. Clin Endocrinol 25: 401–410CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • E. Schuppert
  • H.-J. Schmoll

There are no affiliations available

Personalised recommendations